Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?

Can prostate-specific antigen be used as

Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer?

✍ B. Seckin; C. T. Anthony; B. Murphy; M. S. Steiner 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 444 KB

It is current practice in many clinical trials evaluating new chemotherapy regimens for the treatment of advanced prostate cancer to use prostate-specific antigen (PSA) decline as a response criteria with the assumption that the level of PSA reflects the efficacy of chemotherapy. Advanced prostate c